Legal status · 34 peptides · Records reviewed through
Three public records help with this question. One shows whether FDA approved a product. One shows whether FDA named it on a list of compounding safety risks. Compounding means a pharmacy mixes a drug. The third shows whether sports rules ban it. None of them decides whether you may buy or use a product.
Whether you may buy, sell, or use a product also depends on pharmacy (compounding) rules, a prescription, and state law. Read how U.S. peptide law works.
Have a product in hand? Check if it is a prescription, compounded, or research-only product.
Showing 34 of 34 peptides
| Peptide | FDA status | What the record says | FDA compounding list | Sports rules | Link |
|---|---|---|---|---|---|
| AbaloparatideAlso: Tymlos, BA058, PTHrP analogue | FDA-approved productTymlos | An FDA-approved product exists for defined osteoporosis populations | Not named on this FDA page | Not assessedChecked | |
| AfamelanotideAlso: Scenesse, Nle4-D-Phe7-alpha-MSH, melanocortin-1 agonist | FDA-approved productScenesse | An FDA-approved implant exists for a rare-disease indication | Not named on this FDA page | Not assessedChecked | |
| AOD-9604Also: AOD9604, lipotropin, hGH fragment 176-191 | No FDA-approved product | No FDA-approved AOD-9604 drug product | Nomination withdrawn | ProhibitedChecked | |
| BPC-157Also: BPC 157, Body Protection Compound 157, pentadecapeptide BPC 157 | No FDA-approved product | Still being studied; no FDA-approved BPC-157 product identified | Nomination withdrawn | ProhibitedChecked | |
| BremelanotideAlso: PT-141, Vyleesi, bremelanotide acetate | FDA-approved productVyleesi | An FDA-approved product exists for a narrow indication | Not named on this FDA page | Not assessedChecked | |
| CagrilintideAlso: NNC0174-0833, AM833, NN9833 | No FDA-approved product | Investigational in the United States; no FDA-approved cagrilintide product | Not named on this FDA page | Not assessedChecked | |
| CerebrolysinAlso: Cerebrolysin Ebewe, Cerebrolyzin, FPE 1070 | Approved outside the U.S. only | Authorized in Austria; no FDA-approved Cerebrolysin product was identified in the United States as reviewed August 30, 2026 | Not named on this FDA page | No prohibition identifiedChecked | |
| CJC-1295Also: CJC 1295, CJC-1295 DAC, CJC-1295 with DAC | No FDA-approved product | Still being studied. This review found no FDA-approved CJC-1295 product in the United States. | Nomination withdrawn | ProhibitedChecked | |
| DSIPAlso: Emideltide, Delta sleep-inducing peptide | No FDA-approved product | No FDA-approved U.S. product; the July 2026 advisory vote did not add DSIP to the 503A list | Nomination withdrawnListed as emideltide (DSIP). | Not assessedChecked | |
| EpitalonAlso: Epithalon, AEDG, epitalon acetate | No FDA-approved product | No FDA-approved epitalon drug product | Nomination withdrawn | Not assessedChecked | |
| GHK-CuAlso: copper tripeptide-1, glycyl-L-histidyl-L-lysine copper, GHK copper | No FDA-approved product | No FDA-approved injectable GHK-Cu drug product | Nomination withdrawnFDA lists only injectable GHK-Cu. This entry does not cover topical products. | Not assessedChecked | |
| GHRP-6Also: Growth hormone-releasing peptide 6, Growth hormone-releasing hexapeptide, SKF-110679 | No FDA-approved product | No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026 | Category 2: safety riskListed under the 503B policy. | ProhibitedChecked | |
| GonadorelinAlso: Gonadorelin decapeptide, Factrel, Lutrepulse | Human product discontinued | Former human products were FDA-approved; current human drug records list Factrel and Lutrepulse as discontinued | Not named on this FDA page | ProhibitedApplies to male athletes only.Checked | |
| InsulinAlso: human insulin, insulin analog, rapid-acting insulin | FDA-approved productMultiple human insulin and insulin analog products | Several FDA-approved insulin products exist, including highly similar versions called biosimilars | Not named on this FDA page | ProhibitedA medical exemption can apply.Checked | |
| IpamorelinAlso: ipamorelin acetate, NNC 26-0161, growth hormone secretagogue | No FDA-approved product | Still being studied; no FDA-approved product identified | Category 2: safety riskListed as ipamorelin acetate under the 503B policy. A separate nomination was withdrawn. | ProhibitedChecked | |
| Kisspeptin-10Also: KP-10, KP10, Kisspeptin 112-121 | No FDA-approved product | No FDA-approved Kisspeptin-10 product was identified in the United States as reviewed August 30, 2026 | Category 2: safety riskListed under the 503A policy. | ProhibitedApplies to male athletes only.Checked | |
| LiraglutideAlso: Victoza, Saxenda, GLP-1 analogue | FDA-approved productVictoza, Saxenda | FDA-approved products exist for specific indications | Not named on this FDA page | Not assessedChecked | |
| LL-37Also: LL37, Cathelicidin LL-37, Ropocamptide | No FDA-approved product | No FDA-approved U.S. LL-37 drug found; FDA plans an advisory-committee discussion before the end of February 2027 | Nomination withdrawnListed as cathelicidin LL-37. | Not assessedChecked | |
| Melanotan IIAlso: Melanotan 2, MT-II, MT2 | No FDA-approved product | No approved product in any jurisdiction reviewed | Nomination withdrawn | Not assessedChecked | |
| MOTS-cAlso: MOTS-c peptide, mitochondrial open reading frame 12S rRNA-c | No FDA-approved product | No FDA-approved MOTS-c drug product | Nomination withdrawn | ProhibitedChecked | |
| P21 peptideAlso: P021, P-21, Peptide 021 | No FDA-approved product | Animal and cell studies only. No FDA-approved U.S. P21 product was found. | Not named on this FDA page | Not assessedChecked | |
| RetatrutideAlso: RETA, LY3437943, triple G agonist | No FDA-approved product | Still being studied in the United States; no FDA-approved retatrutide product | Not named on this FDA page | Not assessedChecked | |
| SelankAlso: TP-7, Selanc | No FDA-approved product | No FDA-approved U.S. Selank product was found in the records checked on August 30, 2026 | Nomination withdrawnListed as selank acetate (TP-7). | Not assessedChecked | |
| SemaglutideAlso: Ozempic, Wegovy, Wegovy HD | FDA-approved productOzempic, Wegovy, Wegovy HD, Rybelsus | Some semaglutide prescription products are FDA-approved for specific uses | Not named on this FDA page | No prohibition identifiedChecked | |
| SemaxAlso: Heptapeptide Semax | Approved outside the U.S. only | Registered in Russia; no FDA-approved U.S. product or final 503A listing was identified as reviewed August 30, 2026 | Nomination withdrawn | Not assessedChecked | |
| SermorelinAlso: Geref, GRF 1-29, GHRH(1-29) | Human product discontinued | This review found no current FDA-approved sermorelin product in the United States. Former Geref products were FDA-approved and are no longer sold. FDA said safety or effectiveness was not the reason for their withdrawal. | Not named on this FDA page | ProhibitedChecked | |
| SS-31Also: Elamipretide, MTP-131, Bendavia | FDA-approved productForzinity | Forzinity has FDA accelerated approval for a narrow Barth syndrome use | Not named on this FDA page | Not assessedChecked | |
| TB-500Also: TB500, Ac-LKKTETQ, thymosin beta-4 fragment 17-23 | No FDA-approved product | No FDA-approved TB-500 drug product | Nomination withdrawnListed as thymosin beta-4, fragment (LKKTETQ), also known as TB-500. | ProhibitedChecked | |
| TeduglutideAlso: Gattex, ALX-0600, GLP-2 analogue | FDA-approved productGattex | Teduglutide is a 33-amino-acid GLP-2 analog. In the United States, Gattex (teduglutide) is FDA-approved for people age 1 and older who have short bowel syndrome and depend on fluids or nutrition given through a vein. | Not named on this FDA page | Not assessedChecked | |
| TeriparatideAlso: Forteo, PTH 1-34, recombinant human parathyroid hormone 1-34 | FDA-approved productForteo, approved teriparatide products | FDA-approved products exist for specific osteoporosis populations | Not named on this FDA page | Not assessedChecked | |
| TesamorelinAlso: Egrifta SV, Egrifta WR, TH9507 | FDA-approved productEgrifta SV, Egrifta WR | An FDA-approved product exists for a narrow indication | Not named on this FDA page | ProhibitedChecked | |
| Thymosin alpha-1Also: TA1, Ta1, Tα1 | Approved outside the U.S. only | No FDA-approved thymosin alpha-1 product was identified in the United States as reviewed August 30, 2026 | Nomination withdrawn | No prohibition identifiedChecked | |
| TirzepatideAlso: Mounjaro, Zepbound, GIP/GLP-1 agonist | FDA-approved productMounjaro, Zepbound | Mounjaro and Zepbound have different FDA-approved uses | Not named on this FDA page | Not assessedChecked | |
| VIP peptideAlso: Vasoactive intestinal peptide, Vasoactive intestinal polypeptide | Approval not checked yet | Human physiology and a clinical trial have been studied; product approval needs a separate current check | Not named on this FDA page | Not assessedChecked |
Retatrutide has no single legal status. It depends on the product and how it is supplied. Still being studied in the United States; no FDA-approved retatrutide product. A research use only label does not make a product approved for people. Sports: we have no current sports-rule review for it yet. Rules for buying, selling, and prescribing also depend on how a product is made and sold, and on state law.
Read the full Retatrutide recordSermorelin has no single legal status. It depends on the product and how it is supplied. This review found no current FDA-approved sermorelin product in the United States. Former Geref products were FDA-approved and are no longer sold. FDA said safety or effectiveness was not the reason for their withdrawal. Sports: the anti-doping rules we checked list it as prohibited (checked July 23, 2026). Rules for buying, selling, and prescribing also depend on how a product is made and sold, and on state law.
Read the full Sermorelin recordTesamorelin has no single legal status. It depends on the product and how it is supplied. FDA has approved Egrifta SV and Egrifta WR for set uses. The approval covers only those products, not every product sold under the name Tesamorelin. Sports: the anti-doping rules we checked list it as prohibited (checked August 1, 2026). Rules for buying, selling, and prescribing also depend on how a product is made and sold, and on state law.
Read the full Tesamorelin recordCJC-1295 has no single legal status. It depends on the product and how it is supplied. Still being studied. This review found no FDA-approved CJC-1295 product in the United States. A research use only label does not make a product approved for people. Pharmacy mixing (compounding): FDA had placed it in Category 2 for possible safety risks, and the request was then withdrawn (FDA page dated April 22, 2026). Sports: the anti-doping rules we checked list it as prohibited (checked August 2, 2026). Rules for buying, selling, and prescribing also depend on how a product is made and sold, and on state law.
Read the full CJC-1295 recordSemax has no single legal status. It depends on the product and how it is supplied. Registered in Russia; no FDA-approved U.S. product or final 503A listing was identified as reviewed August 30, 2026. Pharmacy mixing (compounding): FDA had placed it in Category 2 for possible safety risks, and the request was then withdrawn (FDA page dated April 22, 2026). Sports: we have no current sports-rule review for it yet. Rules for buying, selling, and prescribing also depend on how a product is made and sold, and on state law.
Read the full Semax recordIpamorelin has no single legal status. It depends on the product and how it is supplied. Still being studied; no FDA-approved product identified. A research use only label does not make a product approved for people. Pharmacy mixing (compounding): FDA lists it in Category 2 for possible safety risks (FDA page dated April 22, 2026). Sports: the anti-doping rules we checked list it as prohibited (checked July 23, 2026). Rules for buying, selling, and prescribing also depend on how a product is made and sold, and on state law.
Read the full Ipamorelin recordMelanotan II has no single legal status. It depends on the product and how it is supplied. No approved product in any jurisdiction reviewed. A research use only label does not make a product approved for people. Pharmacy mixing (compounding): FDA had placed it in Category 2 for possible safety risks, and the request was then withdrawn (FDA page dated April 22, 2026). Sports: we have no current sports-rule review for it yet. Rules for buying, selling, and prescribing also depend on how a product is made and sold, and on state law.
Read the full Melanotan II recordThe compounding column copies FDA's page of bulk drug substances that may present significant safety risks. FDA marks it current as of . We checked it on .
Each row comes from that peptide's reviewed record, which links the FDA and anti-doping pages it used. Sports statuses come from the World Anti-Doping Agency (WADA) list. Check the current WADA list and your sport's rules before you compete.